Literature DB >> 19718862

[Current status and perspective of heavy ion beam therapy for patients with pelvic recurrence after primarily resected rectal cancer].

Shigeru Yamada1, Makoto Shinoto, Yasuda Shigeo, Hiroshi Imada, Hirotoshi Kato, Tadashi Kamada, Hirohiko Tsujii.   

Abstract

PURPOSE: To evaluate the tolerance for and effectiveness of carbon ion radiotherapy in patients with locally recurrent rectal cancer. PATIENTS AND METHODS: We conducted a phase I / II dose escalation of carbon ion radiotherapy. One hundred twelve patients with 117 sites of locally recurrent cancer receiving carbon ion radiotherapy were analyzed.
RESULTS: None of 112 patients experienced National Cancer Institute-Common Toxicity Criteria grade 3 to 5 acute reactions. The local control rate in patients treated with 67.2 GyE, 70.4 GyE and 73.6 GyE in the present study was 70%, 89% and 97% at 5 years, respectively. The overall survival rates in patients treated with 73.6 GyE were 72% at 3 years and 40% at 5 years.
CONCLUSION: Carbon ion radiotherapy seems to be a safe and effective modality in the management of locally recurrent rectal cancer, providing good local control and offering a survival advantage without unacceptable morbidity.

Entities:  

Mesh:

Year:  2009        PMID: 19718862

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  4 in total

1.  [Efficacy and safety of carbon-ion radiotherapy for locally recurrent rectal cancer: results of the J‑CROS Study 1404 Rectum].

Authors:  Christina Jentsch; Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2019-08       Impact factor: 3.621

2.  Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.

Authors:  Stephanie E Combs; Meinhard Kieser; Daniel Habermehl; Jürgen Weitz; Dirk Jäger; Piero Fossati; Roberto Orrechia; Rita Engenhart-Cabillic; Richard Pötter; Manjit Dosanjh; Oliver Jäkel; Markus W Büchler; Jürgen Debus
Journal:  BMC Cancer       Date:  2012-04-03       Impact factor: 4.430

3.  Radiotherapy for locally recurrent rectal cancer treated with surgery alone as the initial treatment.

Authors:  Hidekazu Tanaka; Takahiro Yamaguchi; Kae Hachiya; Sunaho Okada; Masashi Kitahara; Katsuya Matsuyama; Masayuki Matsuo
Journal:  Radiat Oncol J       Date:  2017-03-31

4.  Fra‑1 enhances the radioresistance of colon cancer cells to X‑ray or C‑ion radiation.

Authors:  Satoshi Endo; Mayumi Fujita; Shigeru Yamada; Kaori Imadome; Fumiaki Nakayama; Tetsuro Isozaki; Takeshi Yasuda; Takashi Imai; Hisahiro Matsubara
Journal:  Oncol Rep       Date:  2018-01-19       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.